Sandoz agrees to pay $540 million to settle antitrust lawsuit, denying any wrongdoing.

Sandoz, a leader in generic and biosimilar medicines, is taking steps to resolve a US antitrust lawsuit. They agreed to pay $275 million to end payer plaintiffs by year-end, with an additional $265 million provision for other claims. This settlement does not admit to wrongdoing and is part of ongoing efforts to address antitrust litigation, with Sandoz continuing to defend against remaining claims.

3 months ago
4 Articles

Further Reading